Please wait while the transcript is being prepared...
0:00
The following session will
cover hit to lead process,
focusing on the main stages of
the hit to lead process
in drug discovery,
focusing on the transition
from initial hit identification
to the selection
and optimization
of promising lead compounds.
We will discuss key screening
techniques, hit triage,
and criteria for
advancing compounds,
including drug likeness
and developability.
Lecture will highlight
the iterative process
of structure activity
relationship studies,
early Ad MET assessments,
and the technologies
that enhance efficiency.
By the end, you
will understand how
the integration of various
scientific disciplines and
risk management strategies drive
successful lead
compound identification
for further drug development.
The journey from initial hit
identification to
the establishment
of robust lead compounds
is central to early
drug discovery.
This phase is the
critical bridge between
biological screening and
medicinal chemistry
optimization.
The main goal is to
refine and prioritize
promising hits into
advanced leads
suitable for further
drug development,
integrating chemistry,
biology, and
computational tools to maximize
success and minimize
costly failures.
Our journey begins with
hit identification,
high throughput,
fragment based, and in
silico screening help
locate molecules capable of
interacting with the
therapeutic target.
In high throughput screening,
millions of compounds
are tested,
but less than one tenth
of 1% become hits.
These undergo rigorous
filtering through
computational and
experimental triage,
